PMID- 8810593
OWN - NLM
STAT- MEDLINE
DCOM- 19961024
LR  - 20220409
IS  - 1073-449X (Print)
IS  - 1073-449X (Linking)
VI  - 154
IP  - 3 Pt 1
DP  - 1996 Sep
TI  - Inflammatory cytokines in patients with persistence of the acute respiratory 
      distress syndrome.
PG  - 602-11
AB  - To determine the relationship between airspace cytokines and cellular 
      inflammatory responses in patients with the acute respiratory distress syndrome 
      (ARDS), we performed bronchoalveolar lavage (BAL) in 82 prospectively identified, 
      mechanically ventilated patients on Days 3, 7, 14, and/or 21 after the onset of 
      ARDS. We studied the relationships between bronchoalveolar lavage fluid (BALF) 
      cell populations and the concentrations of two potent neutrophil (PMN) 
      chemoattractants, interleukin-8 (IL-8) and epithelial cell-derived neutrophil 
      activator-78 (ENA-78); two potent monocyte chemoattractants, monocyte chemotactic 
      peptide-1 (MCP-1) and macrophage inflammatory peptide-1 alpha (MIP-1 alpha); and 
      the early response cytokine interleukin-1 beta (IL-1 beta) and its naturally 
      occurring antagonist, IL-1 receptor antagonist protein (IRAP). We found that all 
      of these cytokines were significantly increased regardless of the duration of 
      ARDS. IL-8 and ENA-78 were the cytokines most strongly and consistently 
      correlated with PMN concentrations in the lung fluids of patients with ARDS, and 
      the correlations were independent of the other cytokines or coexisting lung 
      infection. None of the cytokines tested correlated with macrophage 
      concentrations. MCP-1 was directly correlated with lung injury score on Days 7, 
      14, and 21. Although neither IL-8 nor ENA-78 was associated with outcome, levels 
      of IL-1 beta measured on Day 7 were associated with an increased risk of death 
      (odds ratio [OR] = 2.8; 95% confidence interval [CI] = 1.1 to 7.4). These data 
      demonstrate potential molecular mechanisms of the persistent inflammatory process 
      in the lungs of patients with ARDS.
FAU - Goodman, R B
AU  - Goodman RB
AD  - Medical Research Service, Seattle VA Medical Center, Washington, USA.
FAU - Strieter, R M
AU  - Strieter RM
FAU - Martin, D P
AU  - Martin DP
FAU - Steinberg, K P
AU  - Steinberg KP
FAU - Milberg, J A
AU  - Milberg JA
FAU - Maunder, R J
AU  - Maunder RJ
FAU - Kunkel, S L
AU  - Kunkel SL
FAU - Walz, A
AU  - Walz A
FAU - Hudson, L D
AU  - Hudson LD
FAU - Martin, T R
AU  - Martin TR
LA  - eng
GR  - CA66180/CA/NCI NIH HHS/United States
GR  - HL30542/HL/NHLBI NIH HHS/United States
GR  - HL51072/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (CXCL5 protein, human)
RN  - 0 (Chemokine CXCL5)
RN  - 0 (Chemokines, CXC)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-8)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Bronchoalveolar Lavage Fluid/cytology/immunology
MH  - Chemokine CXCL5
MH  - *Chemokines, CXC
MH  - Cytokines/*isolation & purification
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Intensive Care Units
MH  - Interleukin-8/analogs & derivatives/isolation & purification/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Neutrophils/*metabolism
MH  - Predictive Value of Tests
MH  - Respiration, Artificial
MH  - Respiratory Distress Syndrome/*immunology/mortality
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - 10.1164/ajrccm.154.3.8810593 [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):602-11. doi: 
      10.1164/ajrccm.154.3.8810593.